NICE National Institute for Health and Care Excellence

Single Technology Appraisal

Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) melanoma [ID661]

Committee Papers

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

SINGLE TECHNOLOGY APPRAISAL

Trametinib in combination with dabrafenib for treating advanced (unresectable or metastatic) melanoma

Contents:

1. Pre-Meeting Briefing (PMB)

2. Final Scope and Final Matrix

3. Company submission from **Novartis**
- Company PAS submission
- Submission Appendices
- Correction to PSA addendum

4. **Clarification letters**
- NICE request to the company for clarification on their submission
- Company response to NICE's request for clarification

5. **Patient group, professional group and NHS organisation submission** from:
- British Association of Dermatologists
- Royal College of Physicians
- Royal College of Nursing – *provided no comment response*
- Melanoma Focus

6. **Expert personal perspectives** from:

- Dr Pippa Corrie – clinical expert nominated by Royal College of Physicians (NCRI/RCP/RCR/ACP)
- Dr Paul Nathan – clinical expert, nominated by Melanoma Focus
- Mrs Jackie Hodgetts – clinical expert, nominated by British Association of Specialist Nurses.
- Mrs Gillian Nuttall, Patient expert, nominated by Melanoma UK

7. **Evidence Review Group report** prepared by Liverpool reviews and implementation group.

8. Evidence Review Group report – factual accuracy check

9. Evidence Review Group - Erratum

Any information supplied to NICE which has been marked as confidential, has been redacted. All personal information has also been redacted.